Diagnostic and Evaluation of Hepato-pancreatico-biliary Disease With MRI

Liver Diseases Clinical Trial

Official title:

Diagnostik Und Evaluierung Hepato-pankreatiko-biliärer Erkrankungen Mittels Morphologischer Und Funktioneller Magnetresonanztomographie

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04701567
• Other study ID #: BASEC ID 2020-01313
• Status: Recruiting
• Start date: June 30, 2020
• Est. completion date: December 30, 2023

Study information

• Verified date: January 2021
• Source: University of Zurich
• Contact: Caecilia Reiner, MD
• Phone: +41442551111
• Email: caecilia.reiner[@]usz.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a retrospective review of images from patient data. There is no recruitment necessary for this study. Research Question: Can advanced multiparametric MRI techniques improve the detection and characterization of focal and diffuse liver disease, accurately assess treatment response and predict patient outcomes based on longitudinal monitoring? Hypotheses: Advanced multiparametric MRI techniques improve the detection, characterization and response assessment of focal and diffuse liver disease and can predict serious liver related outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with suspicion for or diagnosed focal and/or diffuse liver or pancreatic disease who underwent MRI of the abdomen.
• 18 years of age and older.

Exclusion Criteria:

• Age less than 18 years.
• Lack of MRI of the abdomen.
• Inadequate image quality.
• Documented rejection to participate in research studies

Related Conditions & MeSH terms

• Liver Diseases
• Pancreas Disease
• Pancreatic Diseases

Intervention

Diagnostic Test:
• Magnetic resonance imaging
Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathology findings in focal and/or diffuse liver disease	Pathology findings in focal and/or diffuse liver disease	1 year
Primary	Pathology findings in focal and/or diffuse pancreatic disease	Pathology findings in focal and/or diffuse pancreatic disease	1 year